Carcinotech has raised $5.3 million of funding as the company looks to build on its traction in the UK and Europe, with U.S. expansion planned later this year. Carcinotech’s Carcino3D technology enables the manufacture of 3D printed micro-tumors, using cells derived from patient biopsies and blood samples to precisely simulate the tumor microenvironment, accelerating ethical drug screening and the delivery of more effective cancer treatments to market.
“Our vision is to be at the forefront of cancer drug testing and provide personalized medicine testing to every individual suffering from cancer to improve their treatment and chance of survival. Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians, Carcinotech aims to significantly accelerate oncology drug development," said Carcinotech CEO Ishani Malhotra.
In October, Carcinotech announced a partnership with Gothenburg-headquartered CELLINK, leveraging CELLINK’s bioprinting solutions and Carcinotech’s expertise in producing bioprinted living tumors to develop cutting-edge cancer models.
Carcinotech has also strengthened its board, chaired by industry veteran Albert Nicholl, and launched a scientific advisory board last year with world renowned oncology leaders.
